REFERENCES
2. Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9:175.
3. Kim SY, Na MJ, Yoon S, et al. The roles and mechanisms of coding and noncoding RNA variations in cancer. Exp Mol Med. 2024;56:1909-20.
4. Esposito R, Lanzós A, Uroda T, et al. Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness. Nat Commun. 2023;14:5463.
5. Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24:430-47.
6. Zhang N, Wang X, Li Y, et al. Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer. Commun Biol. 2025;8:77.
7. Huang A, Zheng H, Wu Z, Chen M, Huang Y. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics. 2020;10:3503-17.
8. Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51:759-74.
9. De-escalation Study for Stage IIa/IIb < 3 cm Seminoma (EDEN). ClinicalTrials.gov ID: NCT05529251. 2024. Available from: https://clinicaltrials.gov/study/NCT05529251?id=NCT05529251&rank=1. [Last accessed on 9 Dec 2025].
10. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res. 2011;717:1-8.
11. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203-22.
12. Cortez MA, Ivan C, Valdecanas D, et al. PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 2016;108:djv303.
13. Metcalf GAD. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene. 2024;43:2135-42.
14. Tylden ES, Delgado AB, Lukic M, et al. Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies. Sci Rep. 2024;14:25022.
15. Bailey S, Ferraresso M, Alonso-Crisostomo L, et al. Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption. Br J Cancer. 2023;129:1451-61.
16. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010;17:215-20.
17. Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7:121.
18. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26:2011-8.
19. Liu J, Zhu S, Tang W, Huang Q, Mei Y, Yang H. Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p. Cancer Cell Int. 2021;21:55.
20. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-58.
21. Zaug AJ, Podell ER, Nandakumar J, Cech TR. Functional interaction between telomere protein TPP1 and telomerase. Genes Dev. 2010;24:613-22.
22. O’Neill TA, Balks MR, López-Martínez J, McWhirter JL. A method for assessing the physical recovery of Antarctic desert pavements following human-induced disturbances: a case study in the Ross Sea region of Antarctica. J Environ Manage. 2012;112:415-28.
23. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008;105:3903-8.
24. Introini-Collison IB, Baratti CM. Opioid peptidergic systems modulate the activity of beta-adrenergic mechanisms during memory consolidation processes. Behav Neural Biol. 1986;46:227-41.
25. Gao Z, Luan X, Wang X, et al. DNA damage response-related ncRNAs as regulators of therapy resistance in cancer. Front Pharmacol. 2024;15:1390300.
26. Li H, Shi Y, Li Y, et al. DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing. Int Immunopharmacol. 2024;137:112475.
27. Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B. 2021;11:340-54.
28. Czochor JR, Sulkowski P, Glazer PM. miR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating error-prone DSB repair. Mol Cancer Res. 2016;14:363-73.
29. Chen J, Zhou C, Li J, et al. miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med. 2018;41:1855-66.
30. Zhou X, Ao X, Jia Z, et al. Non-coding RNA in cancer drug resistance: underlying mechanisms and clinical applications. Front Oncol. 2022;12:951864.
31. Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014;5:e1327.
32. Rogers TJ, Christenson JL, Greene LI, et al. Reversal of triple-negative breast cancer EMT by miR-200c decreases tryptophan catabolism and a program of immunosuppression. Mol Cancer Res. 2019;17:30-41.
33. Juthani R, Punatar S, Mittra I. New light on chemotherapy toxicity and its prevention. BJC Rep. 2024;2:41.
34. Shi F, Su J, Liu Z, Wang J, Wang T. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2. J Cell Biochem. 2019;120:15018-26.
35. Cao L, Wan Q, Li F, Tang CE. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 2018;51:456-61.
36. Jing X, Xie M, Ding K, et al. Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53. Clin Transl Med. 2022;12:e780.
37. Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28:3091-100.
38. Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012;131:445-54.
39. Rama AR, Lara P, Mesas C, et al. Circular sponge against miR-21 enhances the antitumor activity of Doxorubicin against breast cancer cells. Int J Mol Sci. 2022;23:14803.
40. Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, et al. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell Death Discov. 2024;10:372.
41. Kim MW, Moon S, Lee S, et al. Exploring miRNA-target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy. Oncol Lett. 2024;27:158.
42. Wang Z, Ji F. Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncol Lett. 2018;15:4585-91.
43. Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11:97.
44. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180:2490-503.
45. Wei L, Kim SH, Armaly AM, Aubé J, Xu L, Wu X. HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer. NPJ Precis Oncol. 2024;8:286.
46. El Omari N, Bakrim S, Elhrech H, et al. Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma. Eur J Pharm Sci. 2025;208:107057.
47. Gertz M, Fischer F, Nguyen GT, et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc Natl Acad Sci U S A. 2013;110:E2772-81.
48. Itzhak Y, Kalir A, Weissman BA, Cohen S. New analgesic drugs derived from phencyclidine. J Med Chem. 1981;24:496-9.
49. Ceballos MP, Decándido G, Quiroga AD, et al. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines. Toxicol Lett. 2018;289:63-74.
50. Pujia R, Maurotti S, Coppola A, Romeo S, Pujia A, Montalcini T. The potential role of C-peptide in sexual and reproductive functions in type 1 diabetes mellitus: an update. Curr Diabetes Rev. 2022;18:e051021196983.
51. Pavlíková L, Šereš M, Breier A, Sulová Z. The roles of microRNAs in cancer multidrug resistance. Cancers. 2022;14:1090.
52. Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54:1670-94.
53. Yan H, Tang S, Tang S, et al. miRNAs in anti-cancer drug resistance of non-small cell lung cancer: recent advances and future potential. Front Pharmacol. 2022;13:949566.
54. Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.
55. Ji L, Lin Z, Wan Z, et al. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis. 2020;11:250.
56. Gao Y, Zhang W, Liu C, Li G. miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB. Sci Rep. 2019;9:18844.
57. Fattore L, Ruggiero CF, Pisanu ME, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2019;26:1267-82.
58. Bassot A, Dragic H, Haddad SA, et al. Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma. Cell Death Dis. 2023;14:630.
59. Angerilli V, Galuppini F, Businello G, et al. MicroRNAs as predictive biomarkers of resistance to targeted therapies in gastrointestinal tumors. Biomedicines. 2021;9:318.
61. Graziano F, Canestrari E, Loupakis F, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 2010;10:458-64.
62. Pedroza-Torres A, Romero-Córdoba SL, Montaño S, et al. Radio-miRs: a comprehensive view of radioresistance-related microRNAs. Genetics. 2024;227:iyae097.
63. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589-608.
64. Rezaeian AH, Khanbabaei H, Calin GA. Therapeutic potential of the miRNA-ATM axis in the management of tumor radioresistance. Cancer Res. 2020;80:139-50.
65. Zhang P, Wang L, Rodriguez-Aguayo C, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014;5:5671.
66. Tian Y, Tang L, Yi P, et al. MiRNAs in radiotherapy resistance of nasopharyngeal carcinoma. J Cancer. 2020;11:3976-85.
67. Chen Y, Cui J, Gong Y, Wei S, Wei Y, Yi L. MicroRNA: a novel implication for damage and protection against ionizing radiation. Environ Sci Pollut Res Int. 2021;28:15584-96.
68. Salim H, Akbar NS, Zong D, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012;107:1361-73.
69. Xu H, Li W, Wang D. The promising role of miRNAs in radioresistance and chemoresistance of nasopharyngeal carcinoma. Front Oncol. 2024;14:1299249.
70. Ahmad P, Sana J, Slavik M, Slampa P, Smilek P, Slaby O. MicroRNAs involvement in radioresistance of head and neck cancer. Dis Markers. 2017;2017:8245345.
71. Zhang X, Shi H, Lin S, Ba M, Cui S. MicroRNA-216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy. Oncol Rep. 2015;34:1557-64.
72. Zhang Y, Chen Z, Feng L, Jiang P, Li X, Wang X. Ionizing radiation-inducible microRNA-21 induces angiogenesis by directly targeting PTEN. Asian Pac J Cancer Prev. 2019;20:1587-93.
73. Kalajahi HG, Yari A, Amini M, et al. Therapeutic effect of microRNA-21 on differentially expressed hub genes in gastric cancer based on systems biology. Sci Rep. 2023;13:21906.
74. Meng L, Wu H, Wu J, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15:3.
75. Shibru B, Fey K, Fricke S, et al. Detection of immune checkpoint receptors - a current challenge in clinical flow cytometry. Front Immunol. 2021;12:694055.
76. Kipkeeva F, Muzaffarova T, Korotaeva A, et al. The features of immune checkpoint gene regulation by microRNA in cancer. Int J Mol Sci. 2022;23:9324.
77. Martinez-Usatorre A, Sempere LF, Carmona SJ, et al. MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma. Cancer Immunol Res. 2019;7:1013-24.
78. Li D, Liu W, Wang X, et al. Cathelicidin, an antimicrobial peptide produced by macrophages, promotes colon cancer by activating the Wnt/β-catenin pathway. Oncotarget. 2015;6:2939-50.
79. Noman MZ, Janji B, Abdou A, et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology. 2017;6:e1263412.
80. Kim MK, Suh C, Lee DH, et al.; Korean Multiple Myeloma Working Party. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411-6.
81. Nam DY, Rhee JK. Identifying microRNAs associated with tumor immunotherapy response using an interpretable machine learning model. Sci Rep. 2024;14:6172.
82. Li J, Dan K, Ai J. Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis. Front Immunol. 2024;15:1281940.
83. Hücker SM, Fehlmann T, Werno C, et al. Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells. Nat Commun. 2021;12:4316.
84. Chiang NJ, Tang CY, Bai LY, et al. Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study. NPJ Precis Oncol. 2025;9:307.
85. Nguyen MT, Luo YH, Li AL, et al. miRNA as a Modulator Of Immunotherapy And Immune Response In Melanoma. Biomolecules. 2021;11:1648.
86. Motti ML, Minopoli M, Di Carluccio G, Ascierto PA, Carriero MV. MicroRNAs as key players in melanoma cell resistance to MAPK and immune checkpoint inhibitors. Int J Mol Sci. 2020;21:4544.
87. Yadav R, Khatkar R, Yap KC, et al. The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer. Cell Death Discov. 2024;10:414.
88. García-Giménez JL, Saadi W, Ortega AL, et al. miRNAs related to immune checkpoint inhibitor response: a systematic review. Int J Mol Sci. 2024;25:1737.
89. Yu D, Liu X, Han G, et al. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation. Cell Commun Signal. 2019;17:173.
90. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008;105:7004-9.
91. Li K, Liu Y, Zhou Y, et al. An integrated approach to reveal miRNAs’ impacts on the functional consequence of copy number alterations in cancer. Sci Rep. 2015;5:11567.
92. Seviour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 2016;35:691-701.
93. Seo Y, Kim SS, Kim N, Cho S, Park JB, Kim JH. Development of a miRNA-controlled dual-sensing system and its application for targeting miR-21 signaling in tumorigenesis. Exp Mol Med. 2020;52:1989-2004.
94. Okumura S, Hirano Y, Komatsu Y. Stable duplex-linked antisense targeting miR-148a inhibits breast cancer cell proliferation. Sci Rep. 2021;11:11467.
95. Sun L, Liu H, Ye Y, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8:418.
96. Fattore L, Cafaro G, Di Martile M, et al. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance. Oncogene. 2023;42:293-307.
97. Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23:64.
